← Eichor
Study identifier: NCT06648889 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Condition: T-ALL  ·  Sponsor: Goethe University

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, either by modification of standard induction with Isatuximab or by establishing a post-induction therapy for eradication of MRD and thereby evaluates in parallel two different strategies.

This description comes directly from the study's public registry record.

Talk to the study team

Nicola Goekbuget, MD  ·  0049-6963016365  ·  goekbuget@em.uni-frankfurt.de

Always discuss trial participation with your own doctor first.

Locations (15)

University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und HämostaseologieAugsburg, GermanyRecruiting
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt HämatologieBerlin, GermanyRecruiting
Gesundheit Nord Klinikverbund Bremen gGmbH, Klinikum Bremen-Mitte, Med. Klinik IBremen, GermanyRecruiting
Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik IDresden, GermanyRecruiting
University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical ImmunologyDüsseldorf, GermanyRecruiting
University Hospital Erlangen AöR, Department of Medicine 5Erlangen, GermanyRecruiting
Goethe University Hospital Frankfurt, Department of Medicine, Hematology and OncologyFrankfurt am Main, GermanyRecruiting
University Hospital Hamburg-Eppendorf, Department of Medicine IIHamburg, GermanyRecruiting
University Hospital Heidelberg, Department V, Hematology, Oncology and RheumatologyHeidelberg, GermanyRecruiting
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department IIKiel, GermanyRecruiting
University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und ZelltherapieLeipzig, GermanyRecruiting
University Hospital München-Großhadern, Medizinische Klinik und Poliklinik IIIMünchen, GermanyRecruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06648889